CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Seeking Alpha Healthcare
Original article

Nektar gains 5% as jury awards $90M plus interest in Lilly trial

Positive
AI Analysis

Summary

A jury awarded Nektar Therapeutics $90 million plus interest in a legal trial against Eli Lilly. Nektar's stock gained 5% on the verdict announcement.

Outcome Details

Jury awarded $90M plus interest

Importance:6/10
Sentiment:
0.75
litigationjury verdictpatent disputedamages
Related Companies

Read the original article

Published by Seeking Alpha Healthcare on September 25, 2026 11:26 AM

Read Original